FABRAZYME: payments to doctors
Payments that named FABRAZYME as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.6M
- Providers
- 6,058
- Transactions
- 11,542
- Average per transaction
- $398
The per-transaction average — $398 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,058 providers the average total is $757, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $4,379,748 | 95.5% |
| Sanofi-aventis U.S. LLC | $206,628 | 4.5% |
| Sanofi US Services Inc. | $1,626 | 0.0% |